To include your compound in the COVID-19 Resource Center, submit it here.

Zai gets Chinese rights to Five Prime's mAb

Five Prime Therapeutics Inc. (NASDAQ:FPRX) granted Zai Lab Ltd. (NASDAQ:ZLAB) exclusive rights to develop and commercialize FPA144

Read the full 174 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE